SYN-NAT Trademark

Trademark Overview


On Tuesday, May 12, 2020, a trademark application was filed for SYN-NAT with the United States Patent and Trademark Office. The USPTO has given the SYN-NAT trademark a serial number of 88912528. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Saturday, February 15, 2025. This trademark is owned by Medoncare Pharmaceutical Co., Ltd.. The SYN-NAT trademark is filed in the Pharmaceutical Products category with the following description:

Tonics of medicines, namely, medicinal tea; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in preventing prostatitis, benign prostatic hyperplasia, urinary tract infection, gynecological inflammation, gastrointestinal disease; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in blood sugar regulation, liver protection, and as antioxidants, anti-hyperlipidemia, anti-aging, antineoplastic and antiviral agents for medical use; Medicines for human purposes, namely, medicines for the treatment of gastrointestinal disease, skin disease, cardiovascular disease, gout, asthma, nasitis, prostatic cancer, leukemia, melanoma, brain glioma, colon cancer, cervical cancer, thyroid cancer, kidney cancer, stomach cancer and lung cancer, hepatitis B, hepatitis C, AIDS and influenza, prostatitis, benign prostatic hyperplasia and gynecological inflammation, diabetes, sleep disorder and rheum...
syn-nat

General Information


Serial Number88912528
Word MarkSYN-NAT
Filing DateTuesday, May 12, 2020
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateSaturday, February 15, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, April 2, 2024

Trademark Statements


Description of MarkThe mark consists of designed letters "SYN-NAT".
Goods and ServicesTonics of medicines, namely, medicinal tea; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in preventing prostatitis, benign prostatic hyperplasia, urinary tract infection, gynecological inflammation, gastrointestinal disease; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in blood sugar regulation, liver protection, and as antioxidants, anti-hyperlipidemia, anti-aging, antineoplastic and antiviral agents for medical use; Medicines for human purposes, namely, medicines for the treatment of gastrointestinal disease, skin disease, cardiovascular disease, gout, asthma, nasitis, prostatic cancer, leukemia, melanoma, brain glioma, colon cancer, cervical cancer, thyroid cancer, kidney cancer, stomach cancer and lung cancer, hepatitis B, hepatitis C, AIDS and influenza, prostatitis, benign prostatic hyperplasia and gynecological inflammation, diabetes, sleep disorder and rheumatoid arthritis; Medicinal drinks; Capsules sold empty for pharmaceuticals; Pharmaceutical preparations for the treatment of gastrointestinal disease, skin disease, cardiovascular disease, gout, asthma, nasitis, prostatic cancer, leukemia, melanoma, brain glioma, colon cancer, cervical cancer, thyroid cancer, kidney cancer, stomach cancer and lung cancer, hepatitis B, hepatitis C, AIDS and influenza, prostatitis, benign prostatic hyperplasia and gynecological inflammation, diabetes, sleep disorder and rheumatoid arthritis; Chemico-pharmaceutical preparations for tumor-suppression and antiviral treatment; Troches, namely, tablets for use in tumor-suppression, as antivirals and for the treatment of chronic gastrointestinal disease; Tinctura in the nature of medicinal herb extracts; Herbs for medicinal purposes; Nutritional supplements; dietetic foods adapted for medical use, namely, dietetic drinks, dietetic crackers, dietetic sugar for medical use, dietetic sugar substitutes for medical use; Dietary and nutritional supplements; Dietary food supplements; Dietary supplemental drinks; Dietary supplements; Dietetic beverages adapted for medical use; Dietetic foods adapted for medical purposes; Dietetic foods and beverages adapted for medical use; Nutraceuticals for use as a dietary supplement; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Sanitizing preparations for commercial use
Pseudo MarkSYN NAT
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 26, 2020
Primary Code005
First Use Anywhere DateFriday, September 22, 2023
First Use In Commerce DateFriday, April 12, 2024

Trademark Owner History


Party NameMedoncare Pharmaceutical Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressChangsha, Hunan 410205
CN

Party NameMedoncare Pharmaceutical Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressChangsha, Hunan 410205
CN

Trademark Events


Event DateEvent Description
Saturday, August 15, 2020SUSPENSION LETTER WRITTEN
Friday, May 15, 2020NEW APPLICATION ENTERED
Tuesday, May 26, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 8, 2020ASSIGNED TO EXAMINER
Tuesday, January 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, August 15, 2020LETTER OF SUSPENSION E-MAILED
Saturday, August 15, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sunday, August 16, 2020NON-FINAL ACTION WRITTEN
Sunday, August 16, 2020NON-FINAL ACTION E-MAILED
Sunday, August 16, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, August 28, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, January 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 26, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 16, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 16, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 17, 2021SUSPENSION LETTER WRITTEN
Wednesday, February 17, 2021LETTER OF SUSPENSION E-MAILED
Wednesday, February 17, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, September 1, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, March 1, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, February 29, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 17, 2023ASSIGNED TO EXAMINER
Wednesday, March 1, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, August 29, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, March 13, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 2, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 2, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 3, 2024USE AMENDMENT FILED
Tuesday, December 3, 2024TEAS STATEMENT OF USE RECEIVED
Tuesday, June 4, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, February 14, 2025STATEMENT OF USE PROCESSING COMPLETE
Friday, February 14, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, February 15, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Saturday, February 15, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED